**
In a concerning revelation, internal records have surfaced indicating that top officials from the Environmental Protection Agency (EPA) engaged in discussions with Bayer’s CEO, Bill Anderson, regarding ongoing litigation over the controversial glyphosate herbicide. This meeting, held on 17 June, took place just months before the Trump administration intensified its support for Bayer in its legal battles, raising alarm bells about the influence of corporate interests on public health policies.
Meeting Details and Context
The meeting at the EPA was attended by key figures, including Lee Zeldin, the agency’s administrator, and Nancy Beck, who previously held a senior role at the American Chemistry Council and now serves as the principal deputy assistant administrator in the Office of Chemical Safety and Pollution Prevention. The agenda reportedly included discussions on “litigation” issues, notably Bayer’s efforts to mitigate the financial impact of lawsuits filed by thousands of individuals who allege that their use of glyphosate products, such as Roundup, has led to cancer.
This gathering comes against a backdrop of significant public concern. Numerous studies have indicated a potential link between glyphosate use and cancer, prompting legal actions that have already cost Bayer billions in settlements. At the heart of Bayer’s legal strategy is an argument that if the EPA does not mandate a cancer warning on its products, the company should not be held liable for failing to provide such warnings to consumers.
Trump Administration’s Support for Bayer
Since the June meeting, the Trump administration has taken several steps that appear to bolster Bayer’s position. In a filing on 1 December, Solicitor General D John Sauer, appointed by Trump, urged the Supreme Court to take up Bayer’s appeal, which the court subsequently agreed to, scheduling a hearing for 27 April. Additionally, the White House invoked the Defense Production Act to safeguard the production of glyphosate herbicides, effectively offering a form of immunity to manufacturers like Bayer.
Bayer has defended its interactions with the EPA, describing them as part of a standard regulatory process. The company asserts that it has been transparent about its stance on glyphosate litigation, which brings into question the extent of access that large corporations have compared to the general public.
Concerns Over Corporate Influence
Environmental advocates are deeply troubled by the implications of this meeting and subsequent actions. Nathan Donley, the director of environmental health science at the Center for Biological Diversity, expressed alarm over what he sees as a troubling prioritisation of corporate interests over public health. “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans,” he stated.
Legal experts and advocates have echoed these concerns, questioning whether regular citizens, particularly those affected by glyphosate, have been afforded similar opportunities to voice their grievances. Whitney Di Bona, a consumer safety advocate at Drugwatch, highlighted the disparity in access: “It’s concerning that the CEO of a major pesticide company can have private meetings with the EPA to talk about limiting the company’s liability.”
A Pattern of Corporate Access
The meeting between Bayer’s executives and EPA officials raises broader questions about the relationship between government agencies and corporate entities. Naomi Oreskes, a Harvard professor who studies corporate influence on regulation, noted that this interaction exemplifies a pattern where industry leaders have access to government officials in ways that ordinary citizens do not.
Activists from organisations like Moms Across America have also voiced their frustrations, with founder Zen Honeycutt pointing out that chemical companies often exert significant pressure on regulatory agencies. Despite multiple attempts to engage with the EPA regarding the risks of pesticides, her organisation has seen little action taken to address their concerns.
Why it Matters
The implications of this meeting extend far beyond Bayer’s legal troubles. As the EPA engages with corporate leaders while simultaneously sidelining public health concerns, it exemplifies a troubling trend of regulatory capture. The potential prioritisation of corporate profits over the health and safety of the population raises urgent questions about the integrity of environmental governance in the United States. As advocacy for cleaner, safer practices intensifies, it is crucial that the voices of affected citizens are amplified, and that regulatory agencies act in the public’s best interest, not just the interests of powerful corporations.
